BJDX - Bluejay Diagnostics, Inc. Stock Price, Fair Value and News

$3.84-0.06 (-1.54%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BJDX Price Action

Last 7 days

-17.1%

Last 30 days

11.6%

Last 90 days

-45.9%

Trailing 12 Months

-99.7%

BJDX RSI Chart

BJDX Valuation

Market Cap

103.2M

Price/Earnings (Trailing)

-12.02

Price/Sales (Trailing)

377.83

Price/Free Cashflow

-11.14

BJDX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BJDX Fundamentals

BJDX Revenue

Revenue (TTM)

249.0K

BJDX Earnings

Earnings (TTM)

-8.6M

Earnings Growth (Yr)

35.51%

Earnings Growth (Qtr)

40.13%

BJDX Profitability

Return on Equity

-119.88%

Return on Assets

-102.81%

Free Cashflow Yield

-8.98%

BJDX Investor Care

Shares Dilution (1Y)

17256.54%

Diluted EPS (TTM)

-27.35

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q2	Q3	Q4
2024	0	0	0
2023	0	0	0
2022	133.0K	191.0K	249.0K
2021	0	0	75.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

CEO	Mr. Indranil Dey
WEBSITE	bluejaydx.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	16

Bluejay Diagnostics, Inc. Frequently Asked Questions

What is the ticker symbol for Bluejay Diagnostics, Inc.? What does BJDX stand for in stocks?

BJDX is the stock ticker symbol of Bluejay Diagnostics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bluejay Diagnostics, Inc. (BJDX)?

As of Fri Dec 20 2024, market cap of Bluejay Diagnostics, Inc. is 103.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BJDX stock?

You can check BJDX's fair value in chart for subscribers.

Is Bluejay Diagnostics, Inc. a good stock to buy?

The fair value guage provides a quick view whether BJDX is over valued or under valued. Whether Bluejay Diagnostics, Inc. is cheap or expensive depends on the assumptions which impact Bluejay Diagnostics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BJDX.

What is Bluejay Diagnostics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, BJDX's PE ratio (Price to Earnings) is -12.02 and Price to Sales (PS) ratio is 377.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BJDX PE ratio will change depending on the future growth rate expectations of investors.